인공관절치환술 후 예방적 항혈전제 사용 (Thromboprophylaxis after Arthroplasty)

서지정보

· 발행기관 : 한국병원약사회
· 수록지 정보 : 병원약사회지 / 36권 / 1호 / 10 ~ 25페이지
· 저자명 : 김연희, 제남경

초록

Background : Antithrombotic prophylaxis is recommended after knee and hip arthroplasty to prevent venous thromboembolism. The purpose of this study was to investigate the current trend of thromboprophylaxis after knee and hip arthroplasty in South Korea.
Methods : We analyzed Aged Patient Sample data from 2016 compiled by the Health Insurance Review & Assessment Service (HIRA-APS-2016), to estimate the rate of pharmacological thromboprophylaxis.
We also examined the factors influencing the utilization of thromboprophylaxis, according to patient and institutional characteristics.
Results : Thirty-seven percent of patients underwent thromboprophylaxis after knee and hip arthroplasty.
The most utilized antithrombotic agent was rivaroxaban (67.4%), followed by enoxaparin (16.1%).
In terms of population characteristics, factors such as older age, male gender, health insurance type (Medical Aid/Veterans), and comorbidities (peripheral vascular disease and stroke) were identified as risk factors for underuse of thromboprophylaxis.
Conclusions : Less than half of the post-knee and hip arthroplasty patients received thromboprophylaxis.
The use of non-vitamin K oral anticoagulants to replace conventional low molecular weight heparin and warfarin has increased.

영어초록

Background : Antithrombotic prophylaxis is recommended after knee and hip arthroplasty to prevent venous thromboembolism. The purpose of this study was to investigate the current trend of thromboprophylaxis after knee and hip arthroplasty in South Korea.
Methods : We analyzed Aged Patient Sample data from 2016 compiled by the Health Insurance Review & Assessment Service (HIRA-APS-2016), to estimate the rate of pharmacological thromboprophylaxis.
We also examined the factors influencing the utilization of thromboprophylaxis, according to patient and institutional characteristics.
Results : Thirty-seven percent of patients underwent thromboprophylaxis after knee and hip arthroplasty.
The most utilized antithrombotic agent was rivaroxaban (67.4%), followed by enoxaparin (16.1%).
In terms of population characteristics, factors such as older age, male gender, health insurance type (Medical Aid/Veterans), and comorbidities (peripheral vascular disease and stroke) were identified as risk factors for underuse of thromboprophylaxis.
Conclusions : Less than half of the post-knee and hip arthroplasty patients received thromboprophylaxis.
The use of non-vitamin K oral anticoagulants to replace conventional low molecular weight heparin and warfarin has increased.

참고자료

· 없음